title: Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor.
authors.affiliation: Clinical Pharmacology, Bayer Schering Pharma AG, 42096 Wuppertal, Germany. dagmar.kubitza@bayerhealthcare.com
authors.forename: Dagmar
authors.initials: D
authors.lastname: Kubitza
authors.forename: Michael
authors.initials: M
authors.lastname: Becka
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Mueck
authors.forename: Atef
authors.initials: A
authors.lastname: Halabi
authors.forename: Haidar
authors.initials: H
authors.lastname: Maatouk
authors.forename: Norbert
authors.initials: N
authors.lastname: Klause
authors.forename: Volkmar
authors.initials: V
authors.lastname: Lufft
authors.forename: Dominic D
authors.initials: DD
authors.lastname: Wand
authors.forename: Thomas
authors.initials: T
authors.lastname: Philipp
authors.forename: Heike
authors.initials: H
authors.lastname: Bruck
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D019540:Area Under Curve; D015331:Cohort Studies; D003404:Creatinine / Q000378:metabolism; D065427:Factor Xa Inhibitors; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D009025:Morpholines / Q000493:pharmacokinetics* / Q000494:pharmacology*; D051437:Renal Insufficiency / Q000378:metabolism*; D000069552:Rivaroxaban; D013876:Thiophenes / Q000493:pharmacokinetics* / Q000494:pharmacology*
chemical_list: D065427:Factor Xa Inhibitors; D009025:Morpholines; D013876:Thiophenes; D000069552:Rivaroxaban; D003404:Creatinine